How about just studying the safety of lowering LDL-C? Unless there is discordance with LDL-P, does LDL-C matter?
RT @markmccarthyoxf: Fantastic distillation of concerns about this paper from @skathire https://t.co/MYvFy7TFv9
RT @NEJM: Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol https://t.co/TGiLKLw6Bn Mendelian Randomization Study of ACLY an…
RT @NEJM: Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol https://t.co/TGiLKLw6Bn Mendelian Randomization Study of ACLY an…
RT @NEJM: Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol https://t.co/TGiLKLw6Bn Mendelian Randomization Study of ACLY an…
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol https://t.co/TGiLKLw6Bn Mendelian Randomization Study of ACLY and Cardiovascular Disease https://t.co/ISlyNpNSsQ Editorial: Human #Genetics and Drug Development https://t.co/aKZU1L9ezj #card
Fantastic distillation of concerns about this paper from @skathire
RT @stevesphd: Using genetic variants to predict the outcome of a clinical trial (in the same journal edition as the trial itself). Shout o…
Etre ou ne pas être bien doté en génétique en matière de #lipidémie : HMGCR et ACLY même résultat. Probable même impact #cardiovasculaire à terme 🧐 https://t.co/OW25VaqABT
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: And so, my firm conclusion from this paper: a set of 9 SNPs on chromosome 17 that affect LDL-C also affect CVD Less certain:…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
#CausalFriday Using Mendelian randomization to identify novel targets for bloodlipid reduction and cardiovascular prevention https://t.co/Vpsv3kYvlP
RT @minouye271: The first Mendelian randomization study published as a companion to a randomized trial 👇 https://t.co/TvFzTQKiQn https://t.…
Smart, instructive thread about “Mendelian randomization” — recommended.
RT @CAMBRIDGE_CEU: New CEU study led by Brian A Ference, Director of the Cambridge Centre for Naturally Randomized Trials, was published to…
Elegant study of the effect of genetic variants involved in LDL concentration and asociation with cardiovascular disease https://t.co/1Dqvy1FRqX
Mendelian Randomization Study of ACLY and Cardiovascular Disease. https://t.co/qgTcyVjmsF
Worth a read
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @pnatarajanmd: Important considerations when evaluating genetic instruments for Mendelian randomization & resultant claims #ACC19 https:…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
Mendelian Randomization Study of ACLY and Cardiovascular Disease Another interesting area to explore. https://t.co/4THnLVYxFU
RT @mvholmes: I'll leave it for the authors to defend their work. But (1) weak instrument bias in the context of non-overlapping data would…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
So the hypothesis is that the 'ACLY' genetic variants used here https://t.co/Uth6VFj5o7 as an instrument for bempedoic acid are confounded by linkage disequilibrium with other SNPs that associate with LDL-C but not through inhibition of ATP citrate lyase.
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: And so, my firm conclusion from this paper: a set of 9 SNPs on chromosome 17 that affect LDL-C also affect CVD Less certain:…
RT @mvholmes: I'll leave it for the authors to defend their work. But (1) weak instrument bias in the context of non-overlapping data would…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @stevesphd: Using genetic variants to predict the outcome of a clinical trial (in the same journal edition as the trial itself). Shout o…
RT @mvholmes: I'll leave it for the authors to defend their work. But (1) weak instrument bias in the context of non-overlapping data would…
RT @pnatarajanmd: Bempedoic acid (ACLY inhibitor) lowers LDL-C by ~19 mg/dl when added to max statin (https://t.co/p24rzwieWZ) and genetic…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @PeterWilleit: Genetic variants mimicing the effects of ATP citrate lyase inhibitors and statins have similar effects on LDL-C lowering…
RT @minouye271: The first Mendelian randomization study published as a companion to a randomized trial 👇 https://t.co/TvFzTQKiQn https://t.…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @pnatarajanmd: Bempedoic acid (ACLY inhibitor) lowers LDL-C by ~19 mg/dl when added to max statin (https://t.co/p24rzwieWZ) and genetic…
RT @mvholmes: I'll leave it for the authors to defend their work. But (1) weak instrument bias in the context of non-overlapping data would…
RT @mvholmes: I'll leave it for the authors to defend their work. But (1) weak instrument bias in the context of non-overlapping data would…
I'll leave it for the authors to defend their work. But (1) weak instrument bias in the context of non-overlapping data would bias the associations to the null - this clearly isn't the case in this study - not for the lipid associations and not for disease
RT @skathire: And so, my firm conclusion from this paper: a set of 9 SNPs on chromosome 17 that affect LDL-C also affect CVD Less certain:…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
Mendelian Randomization Study of ACLY and Cardiovascular Disease. https://t.co/jG0GVL2nV1
RT @PRB51: $ESPR https://t.co/IaWRdQAC1z
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
$ESPR https://t.co/IaWRdQAC1z
RT @pnatarajanmd: Important considerations when evaluating genetic instruments for Mendelian randomization & resultant claims #ACC19 https:…
ACLYと心血管疾患のメンデルランダム化解析 Mendelian Randomization Study of ACLY and Cardiovascular Disease. B.A. Ference and Others. N Engl J Med 2019; 380:1033-1042 https://t.co/eZOqtQlhIJ
RT @pnatarajanmd: Important considerations when evaluating genetic instruments for Mendelian randomization & resultant claims #ACC19 https:…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @pnatarajanmd: Important considerations when evaluating genetic instruments for Mendelian randomization & resultant claims #ACC19 https:…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
Important considerations when evaluating genetic instruments for Mendelian randomization & resultant claims #ACC19
And so, my firm conclusion from this paper: a set of 9 SNPs on chromosome 17 that affect LDL-C also affect CVD Less certain: that these 9 SNPs can be a proxy for ACLY pharmacologic manipulation https://t.co/atjOuSYtol
The better (bigger) the GWAS the better the MR.
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @CMichaelGibson: Mendelian Randomization: Nature’s Randomized Controlled Trial can teach us so much about pathophysiology and the viab…
Mendelian Randomization: Nature’s Randomized Controlled Trial can teach us so much about pathophysiology and the viability of drug targets. My son @wgibson taught me this.
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
RT @skathire: Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: AC…
Genetic variation in a 900,000 base region around ACLY gene (target of bempedoic acid), LDL-C, & risk for CAD Claim here: ACLY genetic variation affects LDL-C as well as CAD (just like HMGCR genetics) Probably true but have some doubts; follow along
RT @minouye271: The first Mendelian randomization study published as a companion to a randomized trial 👇 https://t.co/TvFzTQKiQn https://t.…
RT @stevesphd: Using genetic variants to predict the outcome of a clinical trial (in the same journal edition as the trial itself). Shout o…
RT @minouye271: The first Mendelian randomization study published as a companion to a randomized trial 👇 https://t.co/TvFzTQKiQn https://t.…
RT @minouye271: The first Mendelian randomization study published as a companion to a randomized trial 👇 https://t.co/TvFzTQKiQn https://t.…
RT @CAMBRIDGE_CEU: New CEU study led by Brian A Ference, Director of the Cambridge Centre for Naturally Randomized Trials, was published to…
RT @CAMBRIDGE_CEU: New CEU study led by Brian A Ference, Director of the Cambridge Centre for Naturally Randomized Trials, was published to…
RT @pnatarajanmd: Bempedoic acid (ACLY inhibitor) lowers LDL-C by ~19 mg/dl when added to max statin (https://t.co/p24rzwieWZ) and genetic…
Mendelian Randomization Study of ACLY and Cardiovascular Disease https://t.co/4je4u6IXdv
Mendelian Randomization Study of <i>ACLY</i> and Cardiovascular Disease. N Engl J Med #cancer #epidemiology https://t.co/hbcZFqK8Hx
RT @minouye271: The first Mendelian randomization study published as a companion to a randomized trial 👇 https://t.co/TvFzTQKiQn https://t.…
RT @stevesphd: Using genetic variants to predict the outcome of a clinical trial (in the same journal edition as the trial itself). Shout o…
RT @CAMBRIDGE_CEU: New CEU study led by Brian A Ference, Director of the Cambridge Centre for Naturally Randomized Trials, was published to…
Genetic variants mimicing the effects of ATP citrate lyase inhibitors and statins have similar effects on LDL-C lowering and subsequent reduction in cardiovascular disease risk. @NEJM paper supports ATP citrate lyase inhibitor as an emerging drug target ht
RT @CAMBRIDGE_CEU: New CEU study led by Brian A Ference, Director of the Cambridge Centre for Naturally Randomized Trials, was published to…
Genetic variants that mimic the effect of statins lower plasma LDL-c levels by the same MoA and were associated with similar effects on the risk of CV disease per unit decrease in the LDL-c level. @diabeteSEEN @sociedadSEEN https://t.co/tNaCQR5orL
RT @pnatarajanmd: Bempedoic acid (ACLY inhibitor) lowers LDL-C by ~19 mg/dl when added to max statin (https://t.co/p24rzwieWZ) and genetic…
RT @pnatarajanmd: Bempedoic acid (ACLY inhibitor) lowers LDL-C by ~19 mg/dl when added to max statin (https://t.co/p24rzwieWZ) and genetic…
RT @pnatarajanmd: Bempedoic acid (ACLY inhibitor) lowers LDL-C by ~19 mg/dl when added to max statin (https://t.co/p24rzwieWZ) and genetic…
RT @pnatarajanmd: Bempedoic acid (ACLY inhibitor) lowers LDL-C by ~19 mg/dl when added to max statin (https://t.co/p24rzwieWZ) and genetic…
RT @minouye271: The first Mendelian randomization study published as a companion to a randomized trial 👇 https://t.co/TvFzTQKiQn https://t.…
RT @pnatarajanmd: Bempedoic acid (ACLY inhibitor) lowers LDL-C by ~19 mg/dl when added to max statin (https://t.co/p24rzwieWZ) and genetic…
Bempedoic acid (ACLY inhibitor) lowers LDL-C by ~19 mg/dl when added to max statin (https://t.co/p24rzwieWZ) and genetic analysis suggests that LDL-C lowering by ACLY inhibition is likely to lower CVD risk (https://t.co/JvYzRmGtZA) @NEJM #ACC19
RT @CAMBRIDGE_CEU: New CEU study led by Brian A Ference, Director of the Cambridge Centre for Naturally Randomized Trials, was published to…